2026-01-05 – Press Releases – www.prnewswire.com
HONG KONG, Jan. 5, 2026 /PRNewswire/ — GenEditBio Limited (“GenEditBio”), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND)…
